Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208


WHO International Standards and Reference Preparations for Cytokines and Growth Factors.

Proudfoot AEI, Wadhwa M.

J Interferon Cytokine Res. 2019 Jul;39(7):438-439. doi: 10.1089/jir.2019.0078. No abstract available.


A knottin scaffold directs the CXC-chemokine-binding specificity of tick evasins.

Lee AW, Deruaz M, Lynch C, Davies G, Singh K, Alenazi Y, Eaton JRO, Kawamura A, Shaw J, Proudfoot AEI, Dias JM, Bhattacharya S.

J Biol Chem. 2019 Jul 19;294(29):11199-11212. doi: 10.1074/jbc.RA119.008817. Epub 2019 Jun 5.


WHO International Standards and Reference Preparations for Cytokines and Growth Factors.

Proudfoot AEI, Wadhwa M.

J Leukoc Biol. 2019 Apr 29. doi: 10.1002/JLB.3LT0419-120. [Epub ahead of print] No abstract available.


Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by Glycosaminoglycans.

Graham GJ, Handel TM, Proudfoot AEI.

Trends Immunol. 2019 Jun;40(6):472-481. doi: 10.1016/ Epub 2019 Apr 18. Review.


Editorial: Chemokines - beyond chemotaxis.

Proudfoot AE, Handel TM, Graham G.

Cytokine. 2018 Sep;109:1. doi: 10.1016/j.cyto.2018.04.036. Epub 2018 Jun 1. No abstract available.


Relevance of CCL3/CCR5 axis in oral carcinogenesis.

da Silva JM, Moreira Dos Santos TP, Sobral LM, Queiroz-Junior CM, Rachid MA, Proudfoot AEI, Garlet GP, Batista AC, Teixeira MM, Leopoldino AM, Russo RC, Silva TA.

Oncotarget. 2017 Apr 6;8(31):51024-51036. doi: 10.18632/oncotarget.16882. eCollection 2017 Aug 1.


Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System.

Proudfoot AEI, Johnson Z, Bonvin P, Handel TM.

Pharmaceuticals (Basel). 2017 Aug 9;10(3). pii: E70. doi: 10.3390/ph10030070. Review.


Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration.

González-Motos V, Jürgens C, Ritter B, Kropp KA, Durán V, Larsen O, Binz A, Ouwendijk WJD, Lenac Rovis T, Jonjic S, Verjans GMGM, Sodeik B, Krey T, Bauerfeind R, Schulz TF, Kaufer BB, Kalinke U, Proudfoot AEI, Rosenkilde MM, Viejo-Borbolla A.

PLoS Pathog. 2017 May 25;13(5):e1006346. doi: 10.1371/journal.ppat.1006346. eCollection 2017 May.


Evasins: Therapeutic Potential of a New Family of Chemokine-Binding Proteins from Ticks.

Bonvin P, Power CA, Proudfoot AE.

Front Immunol. 2016 Jun 7;7:208. doi: 10.3389/fimmu.2016.00208. eCollection 2016.


Modulation of Chemokine Responses: Synergy and Cooperativity.

Proudfoot AE, Uguccioni M.

Front Immunol. 2016 May 19;7:183. doi: 10.3389/fimmu.2016.00183. eCollection 2016. Review.


Chemokines and Glycosaminoglycans.

Proudfoot AE.

Front Immunol. 2015 May 26;6:246. doi: 10.3389/fimmu.2015.00246. eCollection 2015. Review. No abstract available.


The Interaction of Heparin Tetrasaccharides with Chemokine CCL5 Is Modulated by Sulfation Pattern and pH.

Singh A, Kett WC, Severin IC, Agyekum I, Duan J, Amster IJ, Proudfoot AE, Coombe DR, Woods RJ.

J Biol Chem. 2015 Jun 19;290(25):15421-36. doi: 10.1074/jbc.M115.655845. Epub 2015 Apr 23.


Targeting chemokines: Pathogens can, why can't we?

Proudfoot AE, Bonvin P, Power CA.

Cytokine. 2015 Aug;74(2):259-67. doi: 10.1016/j.cyto.2015.02.011. Epub 2015 Mar 6. Review.


 De novo isolation of antibodies with pH-dependent binding properties.

Bonvin P, Venet S, Fontaine G, Ravn U, Gueneau F, Kosco-Vilbois M, Proudfoot AE, Fischer N.

MAbs. 2015;7(2):294-302. doi: 10.1080/19420862.2015.1006993.


Identification of the pharmacophore of the CC chemokine-binding proteins Evasin-1 and -4 using phage display.

Bonvin P, Dunn SM, Rousseau F, Dyer DP, Shaw J, Power CA, Handel TM, Proudfoot AE.

J Biol Chem. 2014 Nov 14;289(46):31846-55. doi: 10.1074/jbc.M114.599233. Epub 2014 Sep 29.


Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis.

Montecucco F, Mach F, Lenglet S, Vonlaufen A, Gomes Quinderé AL, Pelli G, Burger F, Galan K, Dallegri F, Carbone F, Proudfoot AE, Vuilleumier N, Frossard JL.

Eur J Clin Invest. 2014 Oct;44(10):940-50. doi: 10.1111/eci.12327.


Chemokine cooperativity is caused by competitive glycosaminoglycan binding.

Verkaar F, van Offenbeek J, van der Lee MMC, van Lith LHCJ, Watts AO, Rops ALWMM, Aguilar DC, Ziarek JJ, van der Vlag J, Handel TM, Volkman BF, Proudfoot AEI, Vischer HF, Zaman GJR, Smit MJ.

J Immunol. 2014 Apr 15;192(8):3908-3914. doi: 10.4049/jimmunol.1302159. Epub 2014 Mar 17.


TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8.

Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AE, Day AJ, Milner CM.

J Immunol. 2014 Mar 1;192(5):2177-85. doi: 10.4049/jimmunol.1300194. Epub 2014 Feb 5.


International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A.

Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467.


CCL18 exhibits a regulatory role through inhibition of receptor and glycosaminoglycan binding.

Krohn SC, Bonvin P, Proudfoot AE.

PLoS One. 2013 Aug 12;8(8):e72321. doi: 10.1371/journal.pone.0072321. eCollection 2013.


Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice.

Braunersreuther V, Montecucco F, Pelli G, Galan K, Proudfoot AE, Belin A, Vuilleumier N, Burger F, Lenglet S, Caffa I, Soncini D, Nencioni A, Vallée JP, Mach F.

Thromb Haemost. 2013 Oct;110(4):807-25. doi: 10.1160/TH13-04-0297. Epub 2013 Aug 8.


Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models.

Déruaz M, Bonvin P, Severin IC, Johnson Z, Krohn S, Power CA, Proudfoot AE.

FEBS J. 2013 Oct;280(19):4876-87. doi: 10.1111/febs.12463. Epub 2013 Aug 23.


The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans.

Krohn S, Garin A, Gabay C, Proudfoot AE.

Front Immunol. 2013 Jul 15;4:193. doi: 10.3389/fimmu.2013.00193. eCollection 2013.


Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice.

Copin JC, da Silva RF, Fraga-Silva RA, Capettini L, Quintao S, Lenglet S, Pelli G, Galan K, Burger F, Braunersreuther V, Schaller K, Deruaz M, Proudfoot AE, Dallegri F, Stergiopulos N, Santos RA, Gasche Y, Mach F, Montecucco F.

J Cereb Blood Flow Metab. 2013 Apr;33(4):490-8. doi: 10.1038/jcbfm.2012.198. Epub 2012 Dec 19.


Glycosaminoglycan analogs as a novel anti-inflammatory strategy.

Severin IC, Soares A, Hantson J, Teixeira M, Sachs D, Valognes D, Scheer A, Schwarz MK, Wells TN, Proudfoot AE, Shaw J.

Front Immunol. 2012 Oct 16;3:293. doi: 10.3389/fimmu.2012.00293. eCollection 2012.


The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.

Taddei SR, Queiroz-Junior CM, Moura AP, Andrade I Jr, Garlet GP, Proudfoot AE, Teixeira MM, da Silva TA.

Bone. 2013 Jan;52(1):259-67. doi: 10.1016/j.bone.2012.09.036. Epub 2012 Oct 8.


Current status of chemokine receptor inhibitors in development.

Allegretti M, Cesta MC, Garin A, Proudfoot AE.

Immunol Lett. 2012 Jul 30;145(1-2):68-78. doi: 10.1016/j.imlet.2012.04.003. Epub 2012 Apr 20. Review.


Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury.

Nellen A, Heinrichs D, Berres ML, Sahin H, Schmitz P, Proudfoot AE, Trautwein C, Wasmuth HE.

PLoS One. 2012;7(5):e36614. doi: 10.1371/journal.pone.0036614. Epub 2012 May 4.


Properties of 7ND-CCL2 are modulated upon fusion to Fc.

Severin IC, Souza AL, Davis JH, Musolino N, Mack M, Power CA, Proudfoot AE.

Protein Eng Des Sel. 2012 May;25(5):213-22. doi: 10.1093/protein/gzs008. Epub 2012 Mar 2.


Overcoming hurdles in developing successful drugs targeting chemokine receptors.

Schall TJ, Proudfoot AE.

Nat Rev Immunol. 2011 May;11(5):355-63. doi: 10.1038/nri2972. Epub 2011 Apr 15. Review.


Chemokines as targets for therapy.

Garin A, Proudfoot AE.

Exp Cell Res. 2011 Mar 10;317(5):602-12. doi: 10.1016/j.yexcr.2010.12.021. Review. No abstract available.


Therapeutic effects of evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis.

Russo RC, Alessandri AL, Garcia CC, Cordeiro BF, Pinho V, Cassali GD, Proudfoot AE, Teixeira MM.

Am J Respir Cell Mol Biol. 2011 Jul;45(1):72-80. doi: 10.1165/rcmb.2009-0406OC. Epub 2010 Sep 10.


Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice.

Montecucco F, Lenglet S, Braunersreuther V, Pelli G, Pellieux C, Montessuit C, Lerch R, Deruaz M, Proudfoot AE, Mach F.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1371-7. doi: 10.1161/ATVBAHA.110.206011. Epub 2010 Apr 22.


Viral macrophage inflammatory protein-II improves acute rejection in allogeneic rat kidney transplants.

Bedke J, Stojanovic T, Kiss E, Behnes CL, Proudfoot AE, Gröne HJ.

World J Urol. 2010 Aug;28(4):537-42. doi: 10.1007/s00345-010-0556-0. Epub 2010 Apr 18.


Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans.

Severin IC, Gaudry JP, Johnson Z, Kungl A, Jansma A, Gesslbauer B, Mulloy B, Power C, Proudfoot AE, Handel T.

J Biol Chem. 2010 Jun 4;285(23):17713-24. doi: 10.1074/jbc.M109.082552. Epub 2010 Apr 2.


Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice.

Charmoy M, Brunner-Agten S, Aebischer D, Auderset F, Launois P, Milon G, Proudfoot AE, Tacchini-Cottier F.

PLoS Pathog. 2010 Feb 5;6(2):e1000755. doi: 10.1371/journal.ppat.1000755.


Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.

Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AE, Wells TN, Parks WC, Wight TN, Martin TR, Frevert CW.

J Immunol. 2010 Mar 1;184(5):2677-85. doi: 10.4049/jimmunol.0903274. Epub 2010 Feb 1.


Anti-chemokine small molecule drugs: a promising future?

Proudfoot AE, Power CA, Schwarz MK.

Expert Opin Investig Drugs. 2010 Mar;19(3):345-55. doi: 10.1517/13543780903535867. Review.


The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice.

Castor MG, Rezende B, Resende CB, Alessandri AL, Fagundes CT, Sousa LP, Arantes RM, Souza DG, Silva TA, Proudfoot AE, Teixeira MM, Pinho V.

J Immunol. 2010 Mar 1;184(5):2646-54. doi: 10.4049/jimmunol.0902614. Epub 2010 Jan 25.


Structural basis of chemokine sequestration by a tick chemokine binding protein: the crystal structure of the complex between Evasin-1 and CCL3.

Dias JM, Losberger C, Déruaz M, Power CA, Proudfoot AE, Shaw JP.

PLoS One. 2009 Dec 30;4(12):e8514. doi: 10.1371/journal.pone.0008514.


Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis.

Vieira AT, Fagundes CT, Alessandri AL, Castor MG, Guabiraba R, Borges VO, Silveira KD, Vieira EL, Gonçalves JL, Silva TA, Deruaz M, Proudfoot AE, Sousa LP, Teixeira MM.

Am J Pathol. 2009 Dec;175(6):2382-91. doi: 10.2353/ajpath.2009.090093. Epub 2009 Nov 5.


The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function.

Segerer S, Johnson Z, Rek A, Baltus T, von Hundelshausen P, Kungl AJ, Proudfoot AE, Weber C, Nelson PJ.

Mol Immunol. 2009 Aug;46(13):2533-8. doi: 10.1016/j.molimm.2009.05.015. Epub 2009 Jun 12.


Drug discovery targeting the chemokine system--where are we?

Horuk R, Proudfoot AE.

Front Biosci (Elite Ed). 2009 Jun 1;1:209-19. Review.


Chapter 4. Interactions of chemokines with glycosaminoglycans.

Hamel DJ, Sielaff I, Proudfoot AE, Handel TM.

Methods Enzymol. 2009;461:71-102. doi: 10.1016/S0076-6879(09)05404-4.


Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice.

Barcelos LS, Coelho AM, Russo RC, Guabiraba R, Souza AL, Bruno-Lima G Jr, Proudfoot AE, Andrade SP, Teixeira MM.

Microvasc Res. 2009 Sep;78(2):148-54. doi: 10.1016/j.mvr.2009.04.009. Epub 2009 May 8.


Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss.

Brini E, Ruffini F, Bergami A, Brambilla E, Dati G, Greco B, Cirillo R, Proudfoot AE, Comi G, Furlan R, Zaratin P, Martino G.

J Neuroimmunol. 2009 Apr 30;209(1-2):33-9. doi: 10.1016/j.jneuroim.2009.01.022. Epub 2009 Feb 15.


Ticks produce highly selective chemokine binding proteins with antiinflammatory activity.

Déruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TN, Teixeira MM, Power CA, Proudfoot AE.

J Exp Med. 2008 Sep 1;205(9):2019-31. doi: 10.1084/jem.20072689. Epub 2008 Aug 4.


An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo.

Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V, Riva S, Mack M, Déruaz M, Borlat F, Vitte PA, Wells TN, Teixeira MM, Proudfoot AE.

J Leukoc Biol. 2008 Oct;84(4):1101-8. doi: 10.1189/jlb.0108061. Epub 2008 Jul 28.


Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?

Proudfoot AE.

Arthritis Rheum. 2008 Jul;58(7):1889-91. doi: 10.1002/art.23590. No abstract available.


The use of chemokine antagonists in EAE models.

Proudfoot AE, de Souza AL, Muzio V.

J Neuroimmunol. 2008 Jul 31;198(1-2):27-30. doi: 10.1016/j.jneuroim.2008.04.007. Epub 2008 Jun 11. Review.


Supplemental Content

Loading ...
Support Center